NCT04324073View on ClinicalTrials.gov

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

239

Participants

Timeline

Start Date

March 27, 2020

Primary Completion Date

April 21, 2020

Study Completion Date

September 24, 2020

Conditions

Corona Virus Infection

Interventions

DRUG

Sarilumab

(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1

Trial Locations (4)

75005

NECKER Hospital, Paris

Unknown

Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre

Cochin Aphp, Paris

HEGP, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04324073 - Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI | Biotech Hunter | Biotech Hunter